Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-day methadone switching for refractory cancer pain at high opioid doses
ChiCTR2400079719Phase 4Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methadone in cancer pain, sponsored by Zhejiang Cancer Hospital. Primary endpoints: Conversion success rate and Time to pain relief. Started Jan 2024; status: recruiting.
02
Drugs
methadone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2400079719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079719.